Frontiers of Cancer Biology : Current Trends in Cancer Research.

Format:

Book

Author/Creator:

Prasad, Devavarapu Kasi Viswa.

Language:

English

Subjects (All):

Oncogenes.

Antioncogenes.

Physical Description:

1 online resource (322 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Frontiers of Cancer Biology: Current Trends in Cancer Research presents the latest research in cancer, which is advancing day by day.This book provides an introduction to cancer genetics, as well as the roles of genomic instability, oncogenes, proto-oncogenes, tumor suppressor genes, and DNA damage and repair in relation to cancer.

Contents:

Front Cover

Frontiers of Cancer Biology: Current Trends in Cancer Research

Copyright Page

Dedication

Contents

List of contributors

Acknowledgments

1 Introduction to cancer genetics

1.1 Overview of cancer

1.1.1 Historical perspectives on cancer

1.2 The genetic basis of cancer

1.2.1 Defining cancer as a genetic disease

1.2.2 From genes to disease

1.3 The hallmarks of cancer

1.3.1 Sustained proliferative signaling

1.3.2 Evading growth suppressors

1.3.3 Resisting cell death (apoptosis)

1.3.4 Enabling replicative immortality

1.3.5 Inducing angiogenesi

1.3.6 Activating invasion and metastasis

1.3.7 Evading immune destruction

1.3.8 Deregulating cellular metabolism

1.3.9 Genome instability and mutation

1.4 Oncogenes, tumor suppressor genes, and DNA repair genes

1.5 Conclusion

1.5.1 Genetic contributions to cancer

1.5.2 Beyond genetics: epigenetic modifications and tumor microenvironment

1.5.3 Stochastic processes and cellular heterogeneity

1.5.4 The future of cancer research and treatment

1.6 Summary

References

2 Role of genomic instability and gene mutations in carcinogenesis and metastasis

2.1 Introduction

2.2 Genomic instability in cancer

2.2.1 Mechanisms of genomic instability

2.2.2 Historical perspectives on genomic instability in cancer

2.2.3 Genomic instability as a hallmark of cancer

2.2.3.1 Role of genomic instability in tumorigenesis

2.2.3.2 Genetic heterogeneity and tumor evolution

2.2.3.3 Genomic instability and metastasis

2.2.3.4 Impact on therapeutic resistance

2.2.4 Types of genomic instability

2.2.5 Causes of genomic instability

2.2.6 Consequences of genomic instability

2.3 Gene mutations in carcinogenesis

2.3.1 Oncogenes and tumor suppressors

2.3.2 Driver versus passenger mutations.

2.4 Role of genomic instability in metastasis

2.4.1 Epithelial-to-mesenchymal transition

2.4.2 Genetic alterations promoting metastasis

2.5 Targeting genomic instability for cancer therapy

2.5.1 DNA damage response inhibitors

2.5.2 Immunotherapy and genomic instability

2.6 Conclusion

Artificial intelligence disclosure

3 Role of oncogenes, proto-oncogenes, and tumor suppressor genes in cancer progression

3.1 Introduction

3.2 Oncogenes: Definition and mechanism

3.2.1 Mechanisms of oncogene activation: A multifaceted process

3.3 Discovery and significance of oncogenes

3.4 Proto-oncogenes: Normal function and regulation

3.5 Tumor suppressor genes: Function and inactivation

3.5.1 Mechanisms of tumor suppressor gene inactivation

3.6 The two-hit hypothesis and recessive nature of tumor suppressors

3.7 Oncogenes, tumor suppressor genes, and cancer therapeutics

3.8 Conclusion

4 The role of DNA damage and repair in cancer pathogenesis

4.1 Introduction

4.2 DNA damage and its consequences

4.2.1 Types of DNA damage

4.2.2 Endogenous sources of DNA damage

4.2.3 Exogenous sources of DNA damage

4.3 The DNA damage response and repair pathways

4.3.1 Homologous recombination

4.3.2 Nonhomologous end joining

4.3.3 Base excision repair

4.3.4 Nucleotide excision repair

4.3.5 Mismatch repair

4.4 Defective DNA repair and cancer susceptibility

4.4.1 The role of ataxia-telangiectasia-mutated and ataxia-telangiectasia and Rad3-related kinanses in DNA damage response

4.4.2 The role of p53 in DNA damage response

4.4.3 The role of FA proteins in DNA repair

4.4.4 Hereditary cancer syndromes linked to DNA repair defects

4.4.5 The DNA damage signaling network and tumor suppression

4.5 Therapeutic targeting of DNA repair pathways.

4.5.1 Poly(ADP-ribose) polymerase inhibitors and synthetic lethality

4.5.2 Targeting ataxia-telangiectasia-mutated/ataxia-telangiectasia and Rad3-related kinase signaling

4.6 Conclusion

5 Viral genomics and cancer

5.1 Introduction

5.2 Role of bacterial and protozoan infections on the expression of viral genes in cancers

5.3 Effect of microbial dysbiosis on carcinogenesis and metastasis

5.4 Genetic and epigenetic alterations and cancer

5.5 Viral genomics and cancer therapy

5.6 Conclusion

6 Epigenetics and cancer

6.1 Introduction

6.2 Fundamentals of epigenetic regulation

6.2.1 DNA methylation

6.2.2 Histone modifications

6.2.3 Chromatin remodeling complexes

6.2.4 Noncoding RNAs (microRNAs, long noncoding RNAs, and PIWI-interacting RNAs)

6.3 Epigenetic changes in cancer

6.3.1 Global versus site-specific DNA methylation changes

6.3.2 Histone modification profiles in tumors

6.3.3 Noncoding RNAs in oncogenesis

6.3.4 Interaction with key oncogenic pathways

6.3.5 Epigenetic drivers of tumor heterogeneity

6.4 Clinical relevance: epigenetics in diagnosis, prognosis, and therapy

6.4.1 Diagnostic and prognostic biomarkers

6.4.2 Current epigenetic therapies and emerging targeted approaches

6.5 Epigenetics and the tumor microenvironment

6.5.1 Immune-epigenetic interactions

6.5.2 Cancer-associated fibroblasts and epigenetic reprogramming

6.5.3 Endothelial cells and angiogenesis

6.5.4 Hypoxia, metabolism, and epigenetics

6.6 Epigenetics in metastasis and therapy resistance

6.6.1 Epigenetic drivers of metastasis

6.6.2 Epigenetics and therapy resistance

6.6.3 Mechanisms underlying epigenetic plasticity

6.6.4 Clinical strategies to counteract metastasis and resistance

6.7 Future directions and next-generation technologies.

6.8 Conclusion

7 Lung cancer genetics in bridging chemotherapy with advanced therapies for precision oncology

7.1 Introduction

7.2 Genetics and molecular studies

7.3 Treatment: chemotherapy and targeted therapy

7.4 Immunogenetics

7.5 Diagnosis

7.6 Artificial intelligence in lung cancer

7.7 Pharmacogenomics

7.8 Precision medicine

7.9 Liquid biopsies

7.10 Challenges and future directions

7.11 Conclusion

8 Genomics of pediatric cancer

8.1 Introduction

8.2 Prevalence of childhood cancers

8.3 List of childhood cancers

8.4 Risk factors and its types

8.4.1 Demographic risk factors

8.4.2 Environmental factors

8.4.3 Parental risk factors

8.4.4 Intrinsic risk factors

8.4.5 Genetic risk factors

8.4.6 Genetics of cancer

8.5 Genomic studies in childhood cancers

8.6 Is there any diagnosis with genomics in pediatric cancers

8.7 Conclusion

9 Role of gene therapy and immunotherapy in precision medicine

9.1 Introduction

9.2 Gene therapy

9.3 Risks associated with gene therapies

9.4 Types of vectors and its subcategories

9.4.1 Viral vectors

9.4.2 Adenoviral vectors

9.4.3 Retroviruses

9.4.4 Lentiviruses

9.4.5 Adeno-associated viruses

9.4.6 Pox viruses

9.5 Other viruses

9.5.1 Nonviral vectors

9.6 Different methods of gene therapy

9.6.1 Germline gene therapy

9.6.2 Somatic gene therapy

9.6.2.1 Ex vivo delivery

9.6.2.2 In situ delivery

9.6.2.3 In vivo delivery

9.7 Immunotherapy

9.8 Diseases associated with gene therapy

9.9 Diseases associated with immunotherapy

9.10 Diseases associated with gene and immunotherapies

9.10.1 CRISPR-Cas9 gene therapy

9.10.2 Zinc finger protein based gene therapy.

9.10.3 Transcription activator-like effector nucleases

9.10.4 Oncolytic viruses

9.11 Conclusion

Acknowledgment

10 Genetic testing, genetic counseling, and cancer risk assessment during cancer therapy

10.1 Background of cancer

10.1.1 Types of cancers

10.1.2 Prevalence and incidence of cancer

10.1.3 Classification of cancers

10.1.4 Cancer genetics

10.1.4.1 Knudson's hypothesis: the two-hit theory of cancer

10.2 Aim

10.3 Genetic testing

10.4 Genetic counseling

10.5 Hereditary cancer syndromes

10.5.1 Hereditary breast and ovarian cancer syndrome

10.5.1.1 Genetic testing and therapy

10.5.2 Lynch or hereditary nonpolyposis colon cancer syndrome

10.5.3 Multiple endocrine neoplasia

10.5.4 Familial adenomatous polyposis

10.5.4.1 Genes associated with familial adenomatous polyposis

10.5.5 Li-Fraumeni syndrome

10.5.6 Multiple endocrine neoplasia type 1 (MEN1)

10.5.7 Cowden syndrome

10.5.8 Von Hippel-Lindau syndrome

10.5.9 Peutz-Jeghers syndrome

10.5.10 Neurofibromatosis

10.5.11 Tuberous sclerosis complex

10.6 Conclusion

11 Future directions and progress in cancer genetics

11.1 Introduction

11.2 Types of cancers

11.3 Cancer genetics

11.4 Treatment options for cancer

11.4.1 Surgery

11.4.2 Radiation therapy

11.4.3 Chemotherapy

11.4.4 Immunotherapy

11.4.5 Targeted therapy

11.4.6 Hormone therapy

11.4.7 Stem cell transplantation

11.4.8 Precision medicine

11.4.9 Palliative care

11.4.10 Complementary and alternative medicine

11.5 Lifestyle factors in prevention of cancer

11.6 Future directions for treating cancer patients

11.7 Conclusion

Author index

Subject index.

Notes:

Description based on publisher supplied metadata and other sources.

Part of the metadata in this record was created by AI, based on the text of the resource.

ISBN:

0-443-33303-3

9780443333033

OCLC:

1559237770